MedTrace Logo

Faecal Microbiota Transplantation for Liver Cirrhosis

NCT04932577 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-01-24

No results posted yet for this study

Summary

The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.

Conditions

Interventions

BIOLOGICAL

Faecal microbiota transplantation

All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Aalborg University Hospital

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Hvidovre University Hospital

    collaborator OTHER

  • Aalborg University

    collaborator OTHER

  • Esbjerg Hospital - University Hospital of Southern Denmark

    collaborator OTHER

  • Sjælland University Hospital

    collaborator UNKNOWN

  • University of Aarhus

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2026-05-31
Completion
2027-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932577 on ClinicalTrials.gov